Results 261 to 270 of about 14,050 (297)

Surgically Implanted Impella Device for Patients on Impella CP Support Experiencing Refractory Hemolysis

ASAIO Journal, 2022
The Impella CP (Abiomed Inc., Danvers, MA) is widely used in cardiac catheterization laboratories for patients presenting with cardiogenic shock, but it is also known to cause significant hemolysis. The risk of hemolysis can be reduced by properly positioning the device, ensuring an adequate volume status, and using full anticoagulation strategies ...
Ismael Salas de Armas, Amanda Bergeron, Anju Bhardwaj, Maria Patarroyo, Mehmet H. Akay, Dina Al Rameni, Angelo Nascimbene, Manish K. Patel, Jayeshkumar Patel, Juan Marcano, Biswajit Kar, Igor D. Gregoric   +11 more
openaire   +2 more sources

Impella versus Non-Impella for Non-Emergent High-Risk Percutaneous Coronary Intervention.

The American Journal of Cardiology
The benefit of mechanical circulatory support with Impella (Abiomed, Inc., Danvers, Massachusetts) for high-risk percutaneous coronary intervention (HR-PCI) is uncertain. PROTECT III registry data showed improved outcomes with Impella compared with historical data (PROTECT II) but lack a direct comparison with the HR-PCI cohort without Impella support.
Pavan Reddy, I. Merdler, Cheng Zhang, M. Cellamare, I. Ben-Dor, N. Bernardo, Hayder D Hashim, L. Satler, T. Rogers, Ron Waksman   +9 more
semanticscholar   +4 more sources

Single‐access technique for Impella‐assisted PCI: How to take hold of Impella by the smooth handle

Catheterization and Cardiovascular Interventions, 2022
Key Points An increasing number of complex higher risk indicated patients (CHIP) are referred to percutaneous coronary intervention (PCI) and mechanical circulatory support (MCS) provided by devices like the Impella CP is being increasingly used in such procedures.
Giuseppe Tarantini, Tommaso Fabris
openaire   +2 more sources

Reappraisal of the safety and effectiveness of Impella pumps

Nature Reviews Cardiology, 2020
In the decade after the introduction of Impella heart pumps, their use has rapidly increased. However, to date, clinical trial data have not conclusively supported their superiority over other contemporary support devices, and observational experiences have identified signals of increased harm with Impella.
Muthiah Vaduganathan, Mandeep R. Mehra
openaire   +3 more sources

Initial Experiences with the Impella Device in Patients with Cardiogenic Shock [PDF]

The Thoracic and Cardiovascular Surgeon, 2003
We planned a study to assess the safety, feasibility, and efficacy of the Impella micro-axial blood pump in patients with cardiogenic shock.From January 2001 to September 2002 inclusive, 16 patients in cardiogenic shock (maximal inotropic support and with IABP in 11 cases) underwent left ventricle unloading with the Impella pump.
Paul Herijgers, Bart Meyns, Paul Sergeant, Willem Daenen, Willem Flameng, Joseph Dens   +5 more
openaire   +2 more sources

Extended Support With the Impella 5.5: Transplant, ECMO, and Complications

ASAIO journal (1992), 2023
We report midterm results of Impella 5.5 use with focus placed on bridge-outcomes, venoarterial extracorporeal membrane oxygenation (VA-ECMO) transition, complications, and risk factors for mortality. A retrospective review of patients implanted with the
William G. Cohen, D. Rekhtman, A. Iyengar, M. Shin, Michael Ibrahim, Christian A Bermudez, M. Cevasco, J. Wald   +7 more
semanticscholar   +1 more source

Anticoagulation of Impella with a Bivalirudin Purge Solution

ASAIO Journal, 2020
The use of percutaneous ventricular assist devices (VADs) in the acute management of cardiogenic shock is becoming increasingly common. The Impella is a percutaneous VAD, which requires a heparin-containing purge solution to prevent thrombosis and maintain proper pump functionality.
Thomas W. Szymanski, Phillip A. Weeks, Yeunju Lee, Sachin Kumar, Brian Castillo, Biswajit Kar, Igor D. Gregoric   +6 more
openaire   +2 more sources

Outcomes of Impella 5.0 and 5.5 for cardiogenic shock: A single-center 137 patient experience.

Artificial Organs
BACKGROUND This study evaluated the outcomes of patients with cardiogenic shock (CS) supported with Impella 5.0 or 5.5 and identified risk factors for in-hospital mortality.
Yeahwa Hong, Nishant Agrawal, N. Hess, L. A. Ziegler, McKenzie Sicke, Gavin W Hickey, R. Ramanan, Jeffrey Fowler, Danny Chu, P. Yoon, Johannes Bonatti, David J. Kaczorowski   +11 more
semanticscholar   +1 more source

A single healthcare experience with Impella RP

Catheterization and Cardiovascular Interventions, 2020
AbstractObjectivesTo understand the predictors of survival and indications for Impella RP in a single healthcare experience.BackgroundThe Impella RP can be used to temporarily support patients with right ventricular (RV) dysfunction after left ventricular assist device (LVAD) placement or myocardial infarction (MI).
Nikoloz Shekiladze, Jose F. Condado, Pratik B. Sandesara, Jeong Hwan Kim, Chandan Devireddy, Michael McDaniel, Vasilis Babaliaros, Habib Samady, Gautam Kumar, Wissam A. Jaber   +9 more
openaire   +3 more sources

Outcomes with Impella in Cardiogenic Shock

Journal of Cardiac Failure, 2020
Background The Impella (ABIOMED, Danvers, MA) is a temporary left ventricular support device, intended for short-term cardiac support for percutaneous procedures and cardiac shock. The Impella device is available in several sizes capable of producing different flows. It is FDA approved for up to 6 days of support.
J.D. Vega, Wissam Jaber, Andrew L. Smith, Mani A. Daneshmand, Alanna A. Morris, Michael A. Burke, Tamer Attia, Kunal Bhatt, Sonjoy Laskar, Melissa Lyle, Lakshmi Sridharan, Dustin Staloch, Franck Herve Azobou Tonleu   +12 more
openaire   +2 more sources